SynthesisPloS one2022
A comprehensive analysis of clinical, quality of life, and cost-effectiveness outcomes of key treatment options for benign prostatic hyperplasia.
Synthesis in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Tranexamic acid for reducing blood loss in bipolar transurethral resection of the prostate: a systematic review of literature.Einstein (Sao Paulo, Brazil) · 2024Pooled it
- Reoperation after surgical treatment for benign prostatic hyperplasia: a systematic review.Frontiers in endocrinology · 2023Pooled it
- Comprehensive analysis of KAP nursing model combined with digital health management on postoperative self-management in BPH patients.Frontiers in public health · 2025Trial
- Water Vapor Thermal Therapy for Benign Prostatic Hyperplasia: An Umbrella Review and Updated Meta-Analysis.The world journal of men's health · 2026Article
- The Reality of Benign Prostatic Hyperplasia Surgery Price and Reimbursement Across Top United States Hospitals.Urology practice · 2026Article
- Development of the Short Form of the Specific Module of QLICD-BPH (V2.0) for Assessing Quality of Life with Benign Prostatic Hyperplasia by Classical Test Theory, Item Response Theory, and Generalizability Theory.European urology open science · 2026Article
- Perceived partner responsiveness between benign prostatic hyperplasia's symptom index and aging male symptoms.Scientific reports · 2026Article
- MISTs for benign prostatic hyperplasia as first line interventional treatment: Alea iacta est?Prostate cancer and prostatic diseases · 2026Review
- Predictors of Treatment Failure, Second-Line Therapy Outcomes, and Patient Satisfaction after Prostatic Artery Embolization: A Retrospective Study in Benign Prostatic Hyperplasia.Urologia internationalis · 2026Article
- Factors Associated with Health-Related Quality of Life in Patients with Benign Prostatic Hyperplasia Undergoing Pharmacological Treatment: A Cross-Sectional Study.Medicina (Kaunas, Lithuania) · 2025Article
- A flexible cystoscopy device prototype for mechanical tissue ablation based on micro-scale hydrodynamic cavitation: Ex vivo and in vivo studies.Ultrasonics sonochemistry · 2025Article
- Giant Benign Prostatic Hyperplasia: A Case Report.Cureus · 2024Article
- A Review of Combined Phosphodiesterase-5-Inhibitors and α-Blockers versus Phosphodiesterase-5-Inhibitors Alone for Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia.Arab journal of urology · 2024Review
- Outcomes of holmium laser enucleation of the prostate (HoLEP) for very large-sized benign prostatic hyperplasia (over 150 mL): open simple prostatectomy is dead.World journal of urology · 2023Article
- Patients' Perspectives on Attributes While Choosing Minimally Invasive Surgery for Benign Prostatic Hyperplasia Procedures: Experience from Men Undergoing Water Vapor Thermal Therapy.Journal of endourology · 2023Article
- Overview of BPH: Symptom Relief with Dietary Polyphenols, Vitamins and Phytochemicals by Nutraceutical Supplements with Implications to the Prostate Microbiome.International journal of molecular sciences · 2023Review
- Standard approach and future perspective for the management of benign prostatic hyperplasia from a health-economics point of view: the role of transperineal laser ablation.Frontiers in urology · 2023Review
- Controversies in Prostate Artery Embolization: Future Best Practice.Seminars in interventional radiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment options for men with moderate-to-severe lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) have variable efficacy, safety, and retreatment profiles, contributing to variations in patient quality of life and healthcare costs. This study examined the long-term cost-effectiveness of generic combination therapy (CT), prostatic urethral lift (PUL), water vapor thermal therapy (WVTT), photoselective vaporization of the prostate (PVP), and transurethral resection of the prostate (TURP) for the treatment of BPH. A systematic literature review was performed to identify clinical trials of CT, PUL, WVTT, PVP, and TURP that reported change in International Prostate Symptom Score (IPSS) for men with BPH and a prostate volume ≤80 cm3. A random-effects network meta-analysis was used to account for the differences in patient baseline clinical characteristics between trials. An Excel-based Markov model was developed with a cohort of males with a mean age of 63 and an average IPSS of 22 to assess the cost-effectiveness of these treatment options at 1 and 5 years from a US Medicare perspective. Procedural and adverse event (AE)-related costs were based on 2021 Medicare reimbursement rates. Total Medicare costs at 5 years were highest for PUL ($9,580), followed by generic CT ($8,223), TURP ($6,328), PVP ($6,152), and WVTT ($2,655). The total cost of PUL was driven by procedural ($7,258) and retreatment ($1,168) costs. At 5 years, CT and PUL were associated with fewer quality-adjusted life years (QALYs) than WVTT, PVP, and TURP. Compared to WVTT, the incremental cost-effectiveness ratios (ICERs) for both TURP and PVP were above a willingness-to-pay threshold of $50,000/QALY (TURP: $64,409/QALY; PVP: $87,483/QALY). This study provides long-term cost-effectiveness evidence for several common treatment options for men with BPH. WVTT is an effective and economically viable treatment in resource-constrained environments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.